Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.30 USD

76.30
451,069

+1.53 (2.05%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $76.35 +0.05 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Align (ALGN) Ailed by Macroeconomic Issues & Currency Headwind

by Zacks Equity Research

Foreign exchange continues to be a major headwind for Align (ALGN) due to a considerable percentage of its revenues coming from outside the United States.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED), backed by the NuVasive merger and its prominence in the musculoskeletal field.

Zacks Equity Research

Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm

by Zacks Equity Research

Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.

Zacks Equity Research

Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study

by Zacks Equity Research

Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.

Zacks Equity Research

Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes

by Zacks Equity Research

Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.

Zacks Equity Research

Why Haemonetics (HAE) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.

Zacks Equity Research

Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay

by Zacks Equity Research

Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.

Zacks Equity Research

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) due to its series of new product launches and promising growth strategy.

Zacks Equity Research

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on solid prospects of BSI Nano group and raised guidance.

Zacks Equity Research

IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform

by Zacks Equity Research

IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.

Zacks Equity Research

Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics

by Zacks Equity Research

Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.

Zacks Equity Research

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.

Zacks Equity Research

Here's Why Haemonetics (HAE) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay

by Zacks Equity Research

QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.

Zacks Equity Research

LabCorp (LH) to Expand Clinical Trails Access With New Pact

by Zacks Equity Research

LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.

Zacks Equity Research

Medtronic's (MDT) Percept RC DBS System Secures FDA Approval

by Zacks Equity Research

Medtronic's (MDT) latest innovation joins the Percept family, the first and only DBS system with sensing, directionality and advanced programming.

Zacks Equity Research

Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down

by Zacks Equity Research

Neogen's (NEOG) Q2 revenues decline year over year due to lower Animal Safety business.

Zacks Equity Research

Cardinal Health (CAH) Streamlines Operation With New Structure

by Zacks Equity Research

Cardinal Health's (CAH) new reporting structure is likely to streamline operations, providing better visibility of growth areas. At-home solutions and OptiFreight Logistics are possibly the key value creators.

Zacks Equity Research

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.

Zacks Equity Research

Medtronic (MDT) Wins CE Mark for MiniMed 780G With Simplera Sync

by Zacks Equity Research

Medtronic (MDT) secures the CE Mark for the MiniMed 780G system with the disposable, all-in-one Simplera Sync CGM.

Zacks Equity Research

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

by Zacks Equity Research

Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.

Zacks Equity Research

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.